COVID-19 vaccines: Knowing the unknown

被引:21
|
作者
Lv, Huibin [1 ]
Wu, Nicholas C. [2 ]
Mok, Chris K. P. [1 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, HKU Pasteur Res Pole, Hong Kong, Peoples R China
[2] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA
基金
中国国家自然科学基金; 美国国家卫生研究院;
关键词
COVID-19; SARS-CoV-2; Vaccine; ANTIBODY-DEPENDENT ENHANCEMENT; DESIGN; NEUTRALIZATION; PROTECTION; INFECTION; IMMUNITY; SAFETY; VIRUS;
D O I
10.1002/eji.202048663
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vaccine development against SARS-CoV-2 has drawn attention around the globe due to the exploding pandemic. Although COVID-19 is caused by a new coronavirus, SARS-CoV-2, previous research on other coronavirus vaccines, such as FIPV, SARS, and MERS, has provided valuable information for the rapid development of COVID-19 vaccine. However, important knowledge gaps remain - some are specific to SARS-CoV-2, others are fundamental to immunology and vaccinology. Here, we discuss areas that need to be addressed for COVID-19 vaccine development, and what can be learned from examples of vaccine development in the past. Since the beginning of the outbreak, the research progress on COVID-19 has been remarkable. We are therefore optimistic about the rapid development of COVID-19 vaccine.
引用
收藏
页码:939 / 943
页数:5
相关论文
共 50 条
  • [1] Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
    Liu, Jianyang
    Mao, Qunying
    Wu, Xing
    He, Qian
    Bian, Lianlian
    Bai, Yu
    Wang, Zhongfang
    Wang, Qian
    Zhang, Jialu
    Liang, Zhenglun
    Xu, Miao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [2] Safety and Efficacy of the Common Vaccines against COVID-19
    Liu, Ying
    Ye, Qing
    VACCINES, 2022, 10 (04)
  • [3] Delivery Routes for COVID-19 Vaccines
    Park, Jang Hyun
    Lee, Heung Kyu
    VACCINES, 2021, 9 (05)
  • [4] Could live attenuated vaccines better control COVID-19?
    Okamura, Shinya
    Ebina, Hirotaka
    VACCINE, 2021, 39 (39) : 5719 - 5726
  • [5] COVID-19 Vaccines: Current Status and Implication for Use in Indonesia
    Ophinni, Youdiil
    Hasibuan, Anshari S.
    Widhani, Alvina
    Maria, Suzy
    Koesnoe, Sukamto
    Yunihastuti, Evy
    Karjadi, Teguh H.
    Rengganis, Iris
    Djauzi, Samsuridjal
    ACTA MEDICA INDONESIANA, 2020, 52 (04) : 388 - 412
  • [6] Promise and challenges in the development of COVID-19 vaccines
    Chen, Wangxue
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (11) : 2604 - 2608
  • [7] COVID-19 Vaccines in Patients with Maintenance Hemodialysis
    Yen, Cheng-Chieh
    Lin, Shang-Yi
    Chen, Szu-Chia
    Chiu, Yi-Wen
    Chang, Jer-Ming
    Hwang, Shang-Jyh
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (08):
  • [8] COVID-19 vaccines and nanomedicine
    Shapiro, Robert S.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2021, 60 (09) : 1047 - 1052
  • [9] Live unattenuated vaccines for controlling viral diseases, including COVID-19
    Chen, Ji-Ming
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (04) : 1943 - 1949
  • [10] COVID-19 Vaccines: Should We Fear ADE?
    Halstead, Scott B.
    Katzelnick, Leah
    JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (12) : 1946 - 1950